EGFR and non-small cell lung carcinoma: EGFRmut NSCLC tumors express higher levels of CD73 than EGFRwt tumors, and CD73 expression is regulated by the EGFR/Erk signaling pathway in NSCLC.[241] Elevated CD73 levels can inhibit T cell proliferation and effector function, leading to resistance to PD‐(L)1 antibody treatment.